Alvotech (ALVO) Financial Analysis & Valuation | Quarter Chart

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation bios... more
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worl... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$1.78BExchangeNASDAQ
SectorHealthcareIndustryDrug Manufacturers - Specialty & Generic
CountryISCEOLisa Graver
IPO Date2022-06-16CAGR62.44%
Employees1,279Websitewww.alvotech.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
ALVO chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$2.89BP/E-15.44Forward P/E17.82PEG
P/S3.58P/B-9.69P/CF-9.34P/FCF-5.85
Sales$491.95MSales 1Y-12.17%Sales 3Y678.51%Sales 5Y1279.41%
EPS$-0.34EPS 1Y-435.08%EPS 3Y-59.17%EPS 5Y-86.62%
Sales QoQ-0.09%EPS QoQ-6229.03%Sales QoQ Avg-6.17%EPS QoQ Avg-1018.97%
Gross Margin60.45%Operating Margin9.62%Profit Margin-36.51%ROCE3.77%
ROA-11%ROE77%Altman Z Score-1.21Piotroski Score
Current Ratio1.65Quick Ratio0.96Cash Ratio0.43Op. CF Ratio-0.06
Debt/Equity-7.58Debt/Assets0.91Lt Debt/Equity-7.3Lt Debt/Cap.1.18
Intrst Cov.0.3Inventory Turnover0.86Asset Turnover0.31Receivables Turnover4.26
Enterprise Value$2.89BP/E Ratio-15.44
Forward P/E17.82PEG Ratio
P/S Ratio3.58P/B Ratio-9.69
P/CF Ratio-9.34P/FCF Ratio-5.85
EPS$-0.34EPS Growth 1Y-435.08%
EPS Growth 3Y-59.17%EPS Growth 5Y-86.62%
Revenue Growth 1Y-12.17%Gross Margin0.6%
Operating Margin0.1%Profit Margin-0.37%
ROE0.77%ROA-0.11%
ROCE0.04%Current Ratio1.65
Quick Ratio0.96Cash Ratio0.43
Debt/Equity-7.58Interest Coverage0.3
Altman Z Score-1.21Piotroski Score

Alvotech (ALVO) valuation & financials

Alvotech (ALVO) has a market capitalization of $1.78B and trades at a price-to-earnings ratio of -15.4. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).

Alvotech's revenue grew -12.2% over the last year.

Alvotech's next earnings report is scheduled for November 11, 2026 after market close; analysts estimate EPS of $-0.04. Check the earnings calendar to see all companies reporting this week.

📈 Analysts estimate ALVO EPS of $-0.04 for the upcoming quarter. See Alvotech revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Alvotech (ALVO) — frequently asked questions

When does Alvotech (ALVO) report earnings next?

Alvotech is expected to report earnings on November 11, 2026 after market close. Analysts estimate EPS of $-0.04.

What is Alvotech's market cap?

Alvotech (ALVO) has a market capitalization of $1.78B.

What is ALVO's P/E ratio?

Alvotech trades at a price-to-earnings ratio of -15.4, with trailing twelve-month EPS of $-0.34.

How fast is Alvotech growing?

Alvotech's revenue grew -12.2% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)